Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)
Sponsor: Takeda
Listed as NCT03555578, this observational or N/A phase trial focuses on Spinal and Bulbar Muscular Atrophy and remains actively recruiting participants. Sponsored by Takeda, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Recruiting
-
Mar 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Mar 2024 — Jul 2024 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Feb 2023 — Mar 2024 [monthly]
Recruiting
-
Feb 2022 — Feb 2023 [monthly]
Recruiting
-
Jan 2021 — Feb 2022 [monthly]
Recruiting
-
Sep 2018 — Jan 2021 [monthly]
Recruiting
-
Jul 2018 — Sep 2018 [monthly]
Recruiting
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .